Ensysce Biosciences, Inc.

ENSCW

OTC

Healthcare

Biotechnology

La Jolla, CA, US7 employeesensysce.com

—

At a Glance

AI-generated

Ensysce Biosciences faced a challenging fiscal year 2025, with escalating clinical development costs driving deeper operating losses and negative cash flow, while its future viability remains dependent on securing additional capital to fund its Phase 3 trial and ongoing operations.

Revenue breakdown: MPAR (79.3%), TAAPOUD (20.7%).

8-K

Ensysce Biosciences reported a net loss of $10.2 million for the full year 2025, driven by increased R&D spending for its lead drug candidates PF614 and PF614-MPAR, while highlighting clinical and regulatory progress including Phase 3 trial initiation and FDA engagement.

—

Market Cap

—

Revenue

—

Net Income

Employees7

Fundamentals

How The Business Makes Money

Revenue by Segment

MPAR79.3%($8M)

TAAPOUD20.7%($2M)

Activity

What Changed Recently

Management Change

Apr 2, 2026

| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | |---|---|

Delisting

Feb 26, 2026

Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard On February 25, 2026, Ensysce Biosciences Inc. (the “Company”) received a notice (t

Financial Results

Mar 29, 2026

, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor w

Charter Amendment

Mar 22, 2026

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On March 18, 2026, Ensysce Biosciences Inc. (the “Company”) filed with the State of Del

Shareholder Vote

Jan 7, 2026

Submission of Matters to a Vote of Security Holders. (a) The annual meeting of stockholders of Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) was held o

Company Profile

CIK0001716947

ISINUS2936021169

Phone858 263 4196

Address7946 Ivanhoe Avenue, La Jolla, CA, 92037, US

SEC EDGAR